To help patients affected by neurological disorders such as stroke, Parkinson’s, spinal stroke, traumatic brain injury, cerebral palsy and ataxia regain movement abilities for an improved quality of life.
To make GONDOLA™ AMPS a standard treatment option for neurological conditions that cause gait disorders.
Gondola Medical Technologies was founded in Switzerland in 2011 with the goal of developing new technologies in the field of neurorehabilitation to improve quality of life for patients affected by neurological disorders such as stroke, Parkinson’s and ataxia.
The company has made considerable investments in research and clinical studies, with the aim of developing a simple and convenient treatment that can be used by patients independently in the comfort of their own homes. The product of this research is the GONDOLA™ device. . This device provides AMPS (Automated Mechanical Peripheral Stimulation)treatment, which has been shown to be effective in treating gait disorders and balance impairments.
Our headquarters are located within the Lausanne Biopôle science park, one of the world’s top research hubs for companies specialized in life sciences.
In late 2019, Gondola Medical Technologies won an EIC Accelerator Award. The EIC Accelerator is a funding program created by the European Commission to support and promote research in the European Research Area (ERA).
The company continues to conduct clinical studies with internationally renowned neurologists. It has also received substantial support from the American Parkinson Disease Association APDA, and it is in the process of obtaining FDA approval for the GONDOLA™ medical device, which is expected in 2020.
GONDOLA™ has been a CE-marked device since 2012. In Europe, so far, patients in Switzerland, Italy, France, Germany, England, Spain and Belgium have benefited from the GONDOLA treatment. The company has also received requests from patients outside of Europe who have traveled to Switzerland from across the globe to experience the benefits of AMPS treatment.